neoadjuvant chemotherapy

(redirected from Neoadjuvant)
Also found in: Dictionary, Medical, Wikipedia.

neoadjuvant chemotherapy

[‚nē·ō¦aj·ə·vənt ‚kē·mō′ther·ə·pē]
(medicine)
A type of chemotherapy that is used to shrink a tumor prior to surgery or radiation.
References in periodicals archive ?
Although these results suggest that ERAS programs are safe and effective when applied to gastrectomy, we found that most studies investigating ERAS programs for gastric cancer excluded patients who were administered preoperative neoadjuvant chemotherapy.
However, fewer than half of women treated with neoadjuvant chemotherapy achieve a complete response.
In the neoadjuvant phase, enrolled patients received run-in chemotherapy consisting of epirubicin and cyclophosphamide every three weeks for four cycles.
With this background, a descriptive study was aimed to determine the correlation between the WHO response criteria and RECIST response criteria in Locally Advanced Breast Cancer following Neoadjuvant chemotherapy.
Although endocrine therapy has a well-established role in the neoadjuvant setting, this review is confined to the use of NACT.
Finally, she discussed the ongoing SWOG prospective clinical trial S1314, which is testing genomic signatures using the Co-expression Extrapolation (COXEN) model to predict response to neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC).
The partnership added that the US FDA has approved BAVENCIO (avelumab) Injection for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
What are the practice implications of recent research results on screening, neoadjuvant chemotherapy, and an investigational agent that targets recurrent ovarian cancer?
Neoadjuvant therapy, the extent of mesorectal excision, type of reconstruction, anastomotic technique, and protective ileostomy are therapy-related variables.
ALTHOUGH THE USE of neoadjuvant chemotherapy for treatment of women with advanced ovarian cancer has grown significantly in recent years, a new study shows that it is associated with worse overall survival for women with stage IIIC disease, compared with primary cytoreductive surgery.